|
rdf:type |
|
|
lifeskim:mentions |
|
|
pubmed:issue |
5
|
|
pubmed:dateCreated |
1978-1-27
|
|
pubmed:abstractText |
d.1 5 hydroxy-trytophan (600 mg a day) or a placebo were administered during 4 weeks following a double blind cross over design to 11 narcoleptic-cataplectic patients. Daily number of cataplectic and narcoleptic attacks did not vary. The 36 hours polygraphic recordings performed at the end of each treatment exhibit: a trend toward a decrease of the duration of the day time sleep and a significant increase of the duration of the night sleep.
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
IM
|
|
pubmed:chemical |
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
Jul
|
|
pubmed:issn |
0300-0893
|
|
pubmed:author |
|
|
pubmed:issnType |
Print
|
|
pubmed:volume |
27
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
200-3
|
|
pubmed:dateRevised |
2007-11-15
|
|
pubmed:meshHeading |
pubmed-meshheading:336110-5-Hydroxytryptophan,
pubmed-meshheading:336110-Cataplexy,
pubmed-meshheading:336110-Clinical Trials as Topic,
pubmed-meshheading:336110-Double-Blind Method,
pubmed-meshheading:336110-Drug Evaluation,
pubmed-meshheading:336110-Female,
pubmed-meshheading:336110-Humans,
pubmed-meshheading:336110-Imipramine,
pubmed-meshheading:336110-Male,
pubmed-meshheading:336110-Narcolepsy,
pubmed-meshheading:336110-Placebos,
pubmed-meshheading:336110-Sleep,
pubmed-meshheading:336110-Sleep Stages
|
|
pubmed:year |
1977
|
|
pubmed:articleTitle |
Clinical and polygraphic effects of d.1 5 HTP on narcolepsy-cataplexy.
|
|
pubmed:publicationType |
Journal Article,
Clinical Trial,
Controlled Clinical Trial
|
